- Home
- TRP vs TAK Comparison
TRP vs TAK Comparison
Compare TRP & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRP
- TAK
- Stock Information
- Founded
- TRP 1951
- TAK 1781
- Country
- TRP Canada
- TAK Japan
- Employees
- TRP N/A
- TAK N/A
- Industry
- TRP
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- TRP
- TAK Health Care
- Exchange
- TRP Nasdaq
- TAK Nasdaq
- Market Cap
- TRP 50.6B
- TAK 42.2B
- IPO Year
- TRP N/A
- TAK N/A
- Fundamental
- Price
- TRP $45.82
- TAK $14.78
- Analyst Decision
- TRP Hold
- TAK
- Analyst Count
- TRP 3
- TAK 0
- Target Price
- TRP $62.00
- TAK N/A
- AVG Volume (30 Days)
- TRP 1.9M
- TAK 1.7M
- Earning Date
- TRP 05-02-2025
- TAK 05-08-2025
- Dividend Yield
- TRP 5.28%
- TAK 3.88%
- EPS Growth
- TRP 61.28
- TAK 15.39
- EPS
- TRP 3.08
- TAK 0.83
- Revenue
- TRP $9,570,904,339.00
- TAK $29,124,927,177.00
- Revenue This Year
- TRP $10.13
- TAK $8.53
- Revenue Next Year
- TRP $6.27
- TAK N/A
- P/E Ratio
- TRP $15.84
- TAK $35.96
- Revenue Growth
- TRP 3.80
- TAK 9.83
- 52 Week Low
- TRP $34.95
- TAK $12.58
- 52 Week High
- TRP $50.37
- TAK $15.37
- Technical
- Relative Strength Index (RSI)
- TRP 44.02
- TAK 56.44
- Support Level
- TRP $46.31
- TAK $14.75
- Resistance Level
- TRP $50.06
- TAK $15.37
- Average True Range (ATR)
- TRP 1.13
- TAK 0.18
- MACD
- TRP -0.14
- TAK -0.06
- Stochastic Oscillator
- TRP 5.95
- TAK 43.55
About TRP TC Energy Corporation
TC Energy operates natural gas, oil, and power generation assets in Canada and the United States. The firm operates more than 60,000 miles of oil and gas pipelines, more than 650 billion cubic feet of natural gas storage, and about 4,300 megawatts of electric power.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.